EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

被引：2
|
作者：
Hanna, Jerome [1 ]
Rosen, Jan Paul [1 ]
Smethurst, Caroline [1 ]
机构：
[1] Biogen Idec Ltd, Maidenhead, Berks, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2013年 / 84卷 / 11期
关键词：
D O I：
10.1136/jnnp-2013-306573.179
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of natalizumab treatment for relapsing-remitting multiple sclerosis: interim results of the TYSABRI® Observational Programme in Canada
    Jacques, F.
    Bhan, V.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 695 - 696
  • [2] Natalizumab for relapsing-remitting multiple sclerosis: interim data from the Ireland Tysabri Observational Program (iTOP)
    Mcguigan, C.
    Ryan, A.
    Sweeney, B.
    Murphy, S. M.
    Mccabe, D.
    Kinirons, P.
    Murphy, K.
    Hutchinson, M.
    Hanna, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 762 - 763
  • [3] Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
    Butzkueven, Helmut
    Kappos, Ludwig
    Pellegrini, Fabio
    Trojano, Maria
    Wiendl, Heinz
    Patel, Radhika N.
    Zhang, Annie
    Hotermans, Christophe
    Belachew, Shibeshih
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1190 - 1197
  • [4] Efficacy and safety of natalizumab in relapsing-remitting multiple sclerosis: an Italian multicentre observational study
    Bucello, S.
    Sangalli, F.
    Moiola, L.
    Annovazzi, P.
    Rizzo, A.
    Radaelli, M.
    Ghezzi, A.
    Grimaldi, L.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S129 - S130
  • [5] Associations between baseline factors and on-treatment relapses in natalizumab-treated patients with relapsing-remitting multiple sclerosis in the TYSABRI® (natalizumab) observational programme
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Pellegrini, F.
    Trojano, M.
    Zhang, A.
    Belachew, S.
    JOURNAL OF NEUROLOGY, 2013, 260 : S68 - S68
  • [6] Efficacy and safety of Natalizumab treatment for relapsing-remitting multiple sclerosis: results from a retrospective French cohort
    Beyrouti, R.
    Courtois, S.
    Penombre, E.
    Mostoufizadeh, S.
    Cohen, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 649 - 649
  • [7] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [8] Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis
    Cariccio, Veronica Lanza
    Bramanti, Placido
    Mazzon, Emanuela
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 20 : 93 - 99
  • [9] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [10] Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"
    Popova, E. V.
    Brylev, L. V.
    Davydovskaya, M. V.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 79 - +
12345